Investors remain cautious on the Japanese healthcare sector as focus shifts to technology, despite potential dividend support in names like Daiichi Sankyo. Market attention is now focused on upcoming medium-term outlooks from Eisai and Astellas.
Key Takeaways
- 1.Investors maintain a cautious stance toward the Japan pharma/healthcare sector, prioritizing AI and semiconductor stocks instead.
- 2.Share prices for pharmaceutical and healthcare service stocks have declined following guidance for FY3/27, with limited buying interest despite lower valuations.
- 3.Investor sentiment is mixed across specific names: positive on Terumo, bearish on M3 and JMDC, and focused on dividend sustainability for Daiichi Sankyo relative to Takeda.
Table of Contents
- Japan Healthcare: Weekly highlights: Cautious stance on the pharma/healthcare sector continues
- Focus points for next week
- Disclosure Appendix
- Ratings, coverage universe and related definitions
- Global product; distributing entities
- General disclosures
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Akinori Ueda, Ph.D.Tomo Taniguchi
Securities
Daiichi Sankyo4502TerumoOlympusM34483.T4528.TEisai
Themes
Sector Rotation Away from HealthcarePost-Earnings Guidance Caution
Regions
Asia PacificJapan